PFSA
- GlobeNewswire
Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock Sufficient working capital obtained ...
- GlobeNewswire
Profusa Announces 1-for-4 Reverse Stock Split
BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology ...
- GlobeNewswire
Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (NASDAQ:PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement (the ...
- GlobeNewswire
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (NASDAQ:PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a ...
- GlobeNewswire
Profusa Announces 1-for-25 Reverse Stock Split
BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology ...
- GlobeNewswire
Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (NASDAQ:PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved all proposals ...
- GlobeNewswire
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (NASDAQ:PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to ...
- GlobeNewswire
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting
BERKELEY, CA, June 10, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a leading digital health company pioneering next-generation biosensing technologies, today issued the following ...
- GlobeNewswire
Profusa Announces Listing Transfer to The Nasdaq Capital Market
BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous ...
- GlobeNewswire
Former Trump Administration VA Secretary Peter O'Rourke Sr. Joins Quantum Cyber's Board of Directors
WEST PALM BEACH, Fla, May 14, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (NASDAQ:QUCY) ("Quantum Cyber" or the "Company"), a company assembling an AI-powered System-of-Systems autonomous defense ...
- GlobeNewswire
Profusa Receives Favorable Nasdaq Listing Determination
BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous ...
- GlobeNewswire
Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to enhance scale, ...
- GlobeNewswire
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April ...
- GlobeNewswire
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achieve Near-term ...
- GlobeNewswire
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million - $3 million ...
- GlobeNewswire
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered ...
- GlobeNewswire
Profusa Announces 1-for-75 Reverse Stock Split
BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the ...
- GlobeNewswire
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial ...
- GlobeNewswire
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR BERKELEY, Calif, Jan. 16, ...
- GlobeNewswire
Profusa Adds Leading Greek Vascular Surgeon to Customer Base
Dr. Theodosios Bisdas is a renowned vascular surgeon and Head of Clinic of Vascular Surgery at the Athens Medical Center BERKELEY, Calif, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") ...
- GlobeNewswire
Profusa Bolsters European Commercial Network with New French Distributor, MedSell
MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach ...
- GlobeNewswire
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35
New note provides greater repayment flexibility and less dilution with elimination of mandatory amortization payments, increased conversion floor price to $0.35, and expanded mandatory ELOC payments from 33% to 50% ...
- GlobeNewswire
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025
Data from FDA-advised study demonstrates Lumee™ Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with transcutaneous ...
- GlobeNewswire
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026
Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial ...
- GlobeNewswire
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
Study evaluates Lumee™ Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO₂) in peripheral artery disease patients BERKELEY, Calif, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Profusa, ...